BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

Expecting Little Impact From Recent Alnylam Option

 
• By Mandy Jackson
  
BridgeBio's Attruby sped through Q1 sales expectations in ATTR-CM (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Scrip